Monday, 22 December 2025
  
Login

Australia's most trusted
source of pharma news

Monday, 22 December 2025
News

Who made PBAC's Christmas List?

Posted 22 December 2025 AM

A good result for a string of big name drugs that did battle with the PBAC at the November meeting - though there were repeated calls for price cuts and not everyone made it over the finish line.

It was third time lucky for Novo Nordisk which scored a recommendation for its obesity drug Wegovy in patients with established cardiovascular disease with obesity, after failing in obesity in March 2022 and severe obesity in November 2023.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (11)

Clinical & Medical, R&D (10)

Devices (1)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.